A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-Positive Lymphoid Malignancies

Trial Profile

A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-Positive Lymphoid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Navitoclax (Primary) ; Rituximab (Primary)
  • Indications Lymphoproliferative disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Apr 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.
    • 07 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top